Likely to be completed by Jan 2015
Glenmark Pharmaceuticals announced today that its novel molecule 'GRC 27864' for chronic inflammatory diseases including pain is entering human trials. The Company has completed preclinical studies and Phase 1 enabling GLP studies for its selected lead molecule GRC 27864 and has filed a Phase 1 application for first-in-human trial with the MHRA, UK. The Phase 1 studies are to be initiated soon and are likely to be completed by January 2015.Powered by Capital Market - Live News